Except for tumor growth inhibition, monotherapies of STAT3 small-molecule inhibitors are found to decrease immunosuppressive macrophages and Tregs, increase cytolytic CD8+ T-cells and elevate the secretion of proinflammatory cytokines and chemokines [156,158,159]. Here, STAT3 is linked to neoplasm.